Cidara Therapeutics Gross Margin 2014-2022 | CDTX

Current and historical gross margin for Cidara Therapeutics (CDTX) over the last 10 years. The current gross profit margin for Cidara Therapeutics as of December 31, 2022 is %.
Cidara Therapeutics Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-12-31 $0.06B $0.06B 100.00%
2022-09-30 $0.06B $0.06B 100.00%
2022-06-30 $0.03B $0.03B 100.00%
2022-03-31 $0.05B $0.05B 100.00%
2021-12-31 $0.05B $0.05B 100.00%
2021-09-30 $0.05B $0.05B 100.00%
2021-06-30 $0.04B $0.04B 100.00%
2021-03-31 $0.01B $0.01B 100.00%
2020-12-31 $0.01B $0.01B 100.00%
2020-09-30 $0.01B $0.01B 100.00%
2020-06-30 $0.03B $0.03B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.072B $0.064B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.172B 8.84
GSK (GSK) United Kingdom $75.535B 9.47
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.564B 19.57
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.289B 0.00
Biohaven (BHVN) United States $0.959B 0.00
Emergent Biosolutions (EBS) United States $0.444B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.111B 0.00
SQZ Biotechnologies (SQZ) United States $0.019B 0.00
Gelesis Holdings (GLS) United States $0.013B 0.00